

1 **MFN2-dependent recruitment of ATAT1 coordinates mitochondria motility with α -tubulin**
2 **acetylation and is disrupted in CMT2A**

3 A. Kumar¹, D. Larrea², M.E. Pero^{1,3}, P. Infante⁴, M. Conenna⁴, G.J. Shin⁵, W. B. Grueber^{5,6},
4 L. Di Marcotullio^{4,7}, E. Area-Gomez^{2,8}, and F. Bartolini^{1,*}

5
6 ¹Department of Pathology & Cell Biology, Columbia University Irving Medical Center, 10032, New York, NY, USA

7 ²Department of Neurology, Columbia University Irving Medical Center, 10032, New York, NY, USA

8 ³Department of Veterinary Medicine and Animal Production, University of Naples Federico II, 80137, Naples, Italy

9 ⁴Department of Molecular Medicine, 1st University of Rome "La Sapienza", 00161, Rome, Italy

10 ⁵Department of Neuroscience, Zuckerman Mind Brain Behavior Institute, Columbia University, 10027, New York,
11 NY, USA

12 ⁶Department of Physiology & Cellular Biophysics, Zuckerman Mind Brain Behavior Institute, Columbia University,
13 10032, New York, NY, USA

14 ⁷Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome La Sapienza, Rome, Italy.

15 ⁸Current address: Department de Biología Celular y Molecular, Centro de Investigaciones Biológicas, MARGARITA
16 SALAS, CSIC, 28040, Madrid, Spain

17

18

19 ***Corresponding author:** fb2131@columbia.edu

20

21

22

23

24

25 **Running title:** MFN2 coordinates mitochondria motility and tubulin acetylation


26 **Key Words:** Microtubules, acetylated tubulin, ATAT1, HDAC6, MFN2, CMT2A, mitochondria
27 motility, axon degeneration

28 **Abbreviations:** Microtubule, MT; post-translational modifications, PTMs; Charcot-Marie-Tooth
29 Type 2A, CMT2A; Mitofusin-2, MFN2; α -tubulin acetyl transferase 1, ATAT1; Histone
30 deacetylase 6, HDAC6; outer mitochondrial membrane, OMM; endoplasmic reticulum, ER;
31 Mitofusin-1, MFN1; mitochondria-associated ER membranes, MAMs; trichostatin A, TSA;
32 tubulin tyrosine ligase, TTL

33

34 **Abstract**

35 Acetylated microtubules play key roles in the regulation of mitochondria dynamics. It has however
36 remained unknown if the machinery controlling mitochondria dynamics functionally interacts with
37 the α -tubulin acetylation cycle. Mitofusin-2 (MFN2), a large GTPase residing in the mitochondrial
38 outer membrane and mutated in Charcot-Marie-Tooth type 2 disease (CMT2A), is a regulator of
39 mitochondrial fusion, transport and tethering with the endoplasmic reticulum. The role of MFN2
40 in regulating mitochondrial transport has however remained elusive. Here we show that
41 mitochondrial contacts with microtubules are sites of α -tubulin acetylation, which occurs through
42 the MFN2-mediated recruitment of α -tubulin acetyltransferase 1 (ATAT1). We discover that this
43 activity is critical for MFN2-dependent regulation of mitochondria transport, and that axonal
44 degeneration caused by CMT2A MFN2 associated mutations, R94W and T105M, may depend on
45 the inability to release ATAT1 at sites of mitochondrial contacts with microtubules. Our findings
46 reveal a function for mitochondria in regulating acetylated α -tubulin and suggest that disruption
47 of the tubulin acetylation cycle play a pathogenic role in the onset of MFN2-dependent CMT2A.



Highlights

- Mitochondria contacts with MTs are hotspots of α -tubulin acetylation through the recruitment of ATAT1 by MFN2
- Mutations in MFN2 associated with CMT2A disease lose this activity by sequestering ATAT1
- Distal axonal degeneration caused by loss of MFN2 depends on acetylated tubulin-mediated mitochondria transport

62 **eTOC** Recruitment of ATAT1 to mitochondria by MFN2 is critical for axonal viability through
63 the regulation of mitochondria transport, and is disrupted in CMT2A

64 **Introduction**

65 Microtubules (MTs) are key cytoskeletal elements involved in a multitude of functions in all
66 eukaryotic cells. MTs are polarized polymers (comprised of a plus and minus end) constructed by
67 the regulated polymerization of α - and β -tubulin dimers, and their dynamic nature allows them to
68 switch between growth and shrinkage [1]. In neurons, MTs are critical because they support
69 trafficking while providing segregation of functional sub compartments [2]. In vertebrates, MT
70 plus ends uniformly orient toward the distal end of axons, while MTs are arranged with mixed
71 polarity in dendrites [3]. In addition to ensuring structural support, MTs act as intracellular
72 highways for protein motors of the kinesin and dynein family to deliver cargoes via anterograde
73 or retrograde transport respectively. Directional transport is enabled by the structural polarity of
74 MTs, which is recognized by motor proteins that drive transport to either the minus end (dynein)
75 or plus end (most kinesins) [4]. In addition to structural polarity, tubulin post-translational
76 modifications (PTMs) that accumulate on stable MTs are crucial modulators of neuronal transport
77 and their dysregulation has been recently associated with the pathogenesis of both
78 neurodevelopmental and neurodegenerative diseases [5, 6].

79 Acetylated MTs are a subset of stable MTs with key roles in the regulation of axonal transport
80 and mitochondrial dynamics: along with providing preferential tracks for kinesin-1- and dynein-
81 dependent mitochondria transport, two properties of acetylated MTs, their stability and flexibility,
82 make them uniquely adapted to sustain mechanical stress caused by surface tension and
83 organelle/organelle interactions [7-9]. It is perhaps thanks to these properties that mitochondria
84 fusion, fission and ER/mitochondria contact occur selectively on acetylated MTs [10, 11].

85 Acetylation of lys-40 in α -tubulin is predominantly regulated by the tubulin N-
86 acetyltransferase 1 (α TAT1 or ATAT1) and histone deacetylase 6 (HDAC6), two soluble enzymes
87 that catalyze the forward and backward reaction, respectively [12-15]. Tubulin acetylation on lys-
88 40 is an α -tubulin PTM marking the luminal surface of MTs [16, 17], a unique feature that helps
89 the MT lattice cope with mechanical stress via reduced lateral interactions between protofilaments
90 [7] and presumably by facilitating MT self-repair through incorporation of GTP-bound tubulin
91 subunits [9, 18].

92 It is thought that in neurons a large pool of ATAT1 is recruited to the MT lattice by vesicle
93 “hitchhiking” prior to entering the lumen at MT ends or at cracks in the MT lattice [19-22]. In
94 migrating cells, clathrin-coated pits control MT acetylation through a direct interaction of the

95 ATAT1 with the clathrin adaptor AP2 [23]. The rules dictating the selection of the docking sites
96 on vesicles, clathrin-coated pits or MTs are however unknown. Similarly unexplored is whether
97 other organelles can act as docking sites for ATAT1 binding. These are important questions to
98 address, as either hypoacetylation or hyperacetylation of tubulin are predicted to negatively affect
99 MT-dependent functions, either by reducing the local flexibility of the MT (thus promoting further
100 breakage upon bending) or by inhibiting MT dynamics while promoting premature tubulin
101 longevity.

102 In sensory neurons acetylated tubulin is an essential component of the mammalian
103 mechanotransduction machinery through its regulation of cellular stiffness and TRP channel
104 activity [24-26], and loss of acetylated tubulin was reported as a neuropathological feature of
105 vincristine-induced toxicity [27]. Indeed, enhancing tubulin acetylation by HDAC6 inhibitors has
106 been largely successful in restoring axonal integrity and myelination of toxic and genetically
107 inherited forms of peripheral neuropathy, prompting multiple companies to develop and test
108 HDAC6 inhibitors in models of peripheral neuropathies including Charcot-Marie-Tooth disease
109 (CMT) [27-29]. Given the multitude of HDAC6 substrates in addition to tubulins, however, the
110 mechanisms underlying this rescue remain unclear.

111 Charcot-Marie-Tooth type 2A (CMT2A) disease is a predominantly axonal form of familial
112 peripheral neuropathy causing sensory loss that results from degeneration of long peripheral axons
113 [30]. Inherited dominant mutations in the mitochondrial fusion protein mitofusin-2 (MFN2), a
114 large GTPase residing in the outer mitochondrial membrane (OMM) and endoplasmic reticulum
115 (ER), are the most common causes of CMT2A, and the majority of MFN2 mutations affect the
116 amino terminal GTPase domain, with disease onset in the first two years of life and an aggressive
117 clinical course [31, 32]. Like acetylated tubulin, MFN2 plays crucial roles in mitochondria
118 dynamics, including regulation of fusion, motility, and ER/mitochondria contacts [33]. Defects in
119 mitochondria dynamics are typically associated with CMT pathogenesis, including CMT caused
120 by mutant MFN2 [34-37]. However, the mechanism by which mutant MFN2 contributes to
121 CMT2A remains elusive.

122 Together with mitofusin-1 (MFN1), MFN2 regulates mitochondrial fusion, which is essential
123 to maintain proper mitochondrial distribution, shape and degradation [33]. In addition, MFN2
124 plays a critical role in ER-mitochondrial tethering, which is independent of its fusion function, by
125 bonding mitochondria with mitochondria-associated ER membranes (MAMs) to allow for ATP,

126 Ca²⁺ and lipid transfer [34, 38-41]. Accordingly, MFN2 also regulates the rate of cholesterol
127 esterification, which was proposed to be a proxy of MAM function, and the extent of contact points
128 between the ER and mitochondria [42].

129 A fusion-independent role for MFN2 in regulating mitochondrial axonal transport has been
130 reported. Loss of MFN2 or MFN2 disease mutants selectively alter mitochondrial axonal motility
131 and distribution [35, 43, 44]. In addition, MFN2 deficiency in human spinal motor neurons
132 interferes with mitochondrial transport while reducing both mRNA and protein levels of kinesin
133 and dynein motors [45], which may further contribute to impaired mitochondrial motility.
134 Furthermore, both MFN1 and MFN2 interact with mammalian miro (miro1/miro2) and
135 milton/TRAK (OIP106/GRIF1) proteins, members of the molecular machinery that links
136 mitochondria to kinesin motors [43], and overexpression of MFN1 rescues the axonal degeneration
137 caused by MFN2 mutants *in vitro* and *in vivo* [44, 46].

138 Altogether, these data support the notion that MFN2 may directly influence mitochondrial
139 positioning, and that loss of this function contributes to the degeneration of long axons, which are
140 particularly sensitive to failures in meeting local energy demands. This model is consistent with
141 the observation that most of the genes mutated in predominantly axonal forms of CMT have roles
142 in mitochondrial motility, suggesting that impaired mitochondrial transport may be a common
143 mechanism of pathogenesis shared by seemingly unrelated proteins associated with an increased
144 risk for CMT [36]. Despite this compelling evidence, the molecular basis underlying MFN2-
145 dependent regulation of mitochondria positioning remains poorly understood. Furthermore, while
146 loss of MFN2 induces axonal neuropathy, the detailed mechanisms by which MFN2 deficiency
147 results in axonal degeneration are unestablished.

148 In this study, we find that mitochondria contacts with MTs are hotspots of tubulin acetylation
149 through the recruitment of ATAT1 by MFN2 onto mitochondrial outer membranes and that this
150 activity is affected by MFN2 R94W and T105M CMT2A mutations. Furthermore, we provide
151 evidence that axonal degeneration caused by MFN2 loss of function in DRG neurons depends on
152 loss of acetylated tubulin by disrupting mitochondria motility rather than mitochondrial fusion or
153 tethering with the ER.

154

155

156

157 **Results**


158 ***MFN2 is a novel regulator of tubulin acetylation***

159 Despite the intimate relationship between acetylated MTs and mitochondria dynamics, it
160 has remained unknown if the machinery controlling mitochondria motility and/or hetero-
161 homotypic mitochondrial contacts functionally interacts with the α -tubulin acetylation cycle. To
162 test this hypothesis, we measured levels of acetylated α -tubulin in immortalized Mfn2 KO mouse
163 embryonic fibroblast (MEF) cells with reported defects in mitochondria dynamics and functional
164 tethering with the ER [47]. By immunoblot and immunofluorescence analyses, we found that while
165 de-tyrosinated tubulin levels were unaffected, loss of MFN2 reduced acetylated tubulin by more
166 than 50% compared to WT controls (Fig. 1A-E and Fig. S1A-D). Loss of acetylated tubulin in
167 these cells also correlated with a decrease in the abundance of GTP-tubulin islands, the putative
168 entry sites for the tubulin acetyltransferase ATAT1 into the MT lumen and hotspots of MT self-
169 repair by incorporation of GTP-bound tubulin subunits [48-51] (Fig. 1F,G).

170 We measured MT plus end dynamics by following the behavior of individual MTs in WT
171 and Mfn2 KO cells transfected with GFP-tubulin and found that lack of MFN2 expression almost
172 doubled MT dynamicity, an effect due to an increase in MT growth and shrinkage rates (Table 1).
173 The rise in MT dynamicity correlated with a significant loss of MT stability. To test this, we
174 measured the amount of residual MT polymer resisting depolymerization that was induced by mild
175 detergent extraction prior to fixation and immunofluorescence staining (Fig. 1H,I). Importantly,
176 both acetylated tubulin levels and MT dynamics were normalized in Mfn2 KO cells by the HDAC6
177 inhibitor trichostatin A (TSA) (Fig. S1A-D and Table S1), suggesting that the increase in MT
178 dynamicity resulted from loss of α -tubulin acetylation in cells deprived of MFN2.

179

Figure 1



180 **Figure 1. MNF2 regulates α -tubulin acetylation, MT dynamics and MT stability in MEFs.** (A)
 181 Representative immunoblot of WT and Mfn2 KO whole MEF lysates. Acet, acetylated tubulin; deTyr,
 182 detyrosinated tubulin; Mfn2, mitofusin 2; GAPDH, loading control. (B) Representative immunofluorescence
 183 images (max projections from z-stacks) of WT and Mfn2 KO MEFs. Tyr, tyrosinated tubulin; Acet, acetylated

184 tubulin; Tyr, tyrosinated tubulin. (C) Quantification of acetylated (Acet) and (D) deetyrosinated (deTyr) tubulin
 185 signal normalized to WT control levels (n=150-175 cells). (E) Quantification of acetylated (Acet) to tyrosinated
 186 (Tyr) tubulin immunofluorescence signal intensity ratio in WT and Mfn2 KO MEFs. (F) GTP tubulin staining
 187 in WT and Mfn2 KO MEFs using hMB11 antibody staining. (G) Quantification of GTP-tubulin (MB11)
 188 immunofluorescence signal intensity associated with MTs in WT and Mfn2 KO MEFs (n=20-25 cells). (H)
 189 Representative immunofluorescence images of residual MT staining (DM1A) in WT and Mfn2 KO extracted
 190 MEFs. (I) Quantification of residual DM1A tubulin levels in WT and Mfn2 KO MEFs treated as in H (n=100-
 191 125 cells). Data are expressed as median with interquartile range. n= 3 independent experiments * p<0.05; **
 192 p<0.01; ns non-significant by Mann–Whitney U test. Scale bars, 10 μ m.

	WT	Mfn2 KO
Growth rate (μ m/s)	0.05 \pm 0.02	0.13 \pm 0.006 *
Shrinkage rate (μ m/s)	0.07 \pm 0.004	0.12 \pm 0.01 *
Catastrophe freq. (s ⁻¹)	0.06 \pm 0.006	0.06 \pm 0.004
Rescue freq. (s ⁻¹)	0.08 \pm 0.006	0.08 \pm 0.006
% Growth	35.5 \pm 1.92	44.15 \pm 0.95 ***
% Shrinkage	34.05 \pm 0.87	36.48 \pm 1.27 *
% Pause	29.58 \pm 0.62	20.1 \pm 1.45
MT lifetime (s)	58.25 \pm 2.14	60.5 \pm 1.73
MT dynamicity (μ m/min)	5.96 \pm 0.42	10.43 \pm 0.25 ***
Number of MTs	20	20

Table 1. MFN2 regulates MT dynamics in MEFs. MT dynamics were measured from time-lapse analysis of GFP-tubulin-labeled MTs using epifluorescence microscopy (1f/5s). Parameters characterizing MT dynamics, such as the growth rate, the shrinkage rate, the frequency of ‘catastrophe’ (transitions from growth/pause to shortening) and ‘rescue’ (transitions from shortening to growth/pause) events, as well as the average amount of time spent by MTs in growth, shrinkage and pausing, MT lifetime and MT dynamicity (#of growth + shrinkage events/lifetime). Data are mean \pm SEM from 3 independent experiments. * p<0.05; *** p<0.001 by Student’s t-test.

193

194

195

196 ***Tubulin acetylation is required for MFN2-dependent regulation of mitochondrial motility but***
197 ***not for mitochondrial fusion or functional tethering to the ER***

198 We observed that the co-localization of mitochondria with MTs was reduced in Mfn2 KO
199 cells but was restored when Mfn2 KO cells were treated with TSA (Fig. S1E,F). Hence, we
200 determined whether increasing acetylated tubulin levels by TSA also reestablished regular
201 mitochondria dynamics, and/or mitochondrial associated ER-membrane (MAM) function,
202 mitochondrial features affected by loss of MFN2 expression (Fig. 2). We observed that TSA
203 normalized both central and peripheral mitochondrial displacement velocity as well as
204 mitochondria distribution and contacts with MTs in Mfn2 KO cells (Fig. 2A-C and Fig. S1E,F).
205 However, while mitochondria elongated morphology was partially reestablished in Mfn2 KO cells
206 treated with TSA, increasing acetylated tubulin completely failed to recover mitochondria fusion,
207 an activity significantly compromised in cells deprived of MFN2 (Fig. 2D,E). Identical results
208 were obtained using tubacin, a more potent and highly selective HDAC6 inhibitor (Fig. 2F-I) [52].

209 We inquired whether the rescue of mitochondrial dynamics was dependent on acetylated
210 tubulin or a general gain in MT stability resulting from tubulin acetylation. To test this, we adopted
211 Iqgap1 KO MEFs, a cell line with normal MFN2 levels but naturally deprived of detyrosinated
212 and acetylated MTs, two independent subsets of stable MTs [53] (Fig. S2). By analogy with Mfn2
213 KO cells, we found that loss of IQGAP1 also resulted in defective MT and mitochondrial dynamics
214 (Fig. S3 and Table S2), consistent with a role for modified MTs in regulating mitochondria
215 homeostasis. However, increasing detyrosinated tubulin by tubulin tyrosine ligase (TTL) silencing
216 did not normalize mitochondrial dynamics to the extent of TSA treatment (Fig. S3E-I), suggesting
217 that rescue of mitochondria dynamics was dependent on the selective increase in acetylated tubulin
218 rather than a general gain in MT stability (Fig. S2,3 and Table S2).

219 Next, we tested the effects of restoring acetylated tubulin levels on loss of MAM function
220 by analyzing the synthesis and transfer of phospholipid between ER and mitochondria, a known
221 proxy of MAM activity, as well as changes in lipid classes by lipidomics analysis in Mfn2 KO
222 cells [34, 54]. MAM is a transient specialized subdomain of the ER with the characteristics of a
223 lipid raft. The temporary formation of MAM domains in the ER regulates several metabolic
224 pathways, including lipid and Ca²⁺ homeostasis and mitochondrial activity [38, 55]. Alterations in
225 the formation of MAM domains have been reported to induce significant changes in lipid
226 metabolism in several pathologies including neurodegenerative disease [39, 55]. In particular,

227 defects in MAM activity have significant detrimental effects on the regulation of cholesterol and
228 its esterification into cholesteryl esters [56]. Equally important, defects in MAM impair the
229 regulation of sphingomyelin (SM) turnover and its hydrolysis into ceramide species [57, 58].

230 We found that Mfn2KO cells display significant increases in sphingomyelin and
231 cholesterol with concomitant decreases in cholesteryl esters and ceramide levels (Fig. 2J,K) and
232 that these changes could be rescued by HDAC6 inhibition (Fig. 2J,K). However, TSA failed to
233 normalize MAM-dependent phospholipid synthesis measured by incorporation of radiolabeled ³H-
234 Ser into newly synthesized ³H-PtdSer (PS) and (H) ³H-PtdEtn (PE) (Fig. 2L).

235 Altogether, our results demonstrate a previously unrecognized role for MFN2 in the
236 regulation of α -tubulin acetylation and suggest that this activity is important for MFN2-dependent
237 control of mitochondria motility and lipid-raft MAM composition, but not for MFN2-dependent
238 mitochondrial fusion or functional mitochondrial/ER tethering. Furthermore, our results in Iqgap1
239 KO cells support the notion that acetylated tubulin is a modulator of mitochondria dynamics *per*
240 *se* and suggest that the machinery controlling mitochondria motility may regulate the α -tubulin
241 acetylation cycle at sites of mitochondria contacts with MTs.

242

243

244

245

246

247

248

249

250


251

252

253

254

Figure 2



255 **Figure 2. Restoring acetylated tubulin in Mfn2 KO MEFs rescues mitochondria motility and cholesterol**
 256 **esterification but not mitochondria fusion or phospholipid synthesis defects.** (A) WT and Mfn2 KO cells
 257 were stained with mitoTracker Red and treated with TSA (10 μ M) or vehicle control for 6 h. Scale bar, 10 μ m.
 258 (B) Quantification of mitochondrial displacement velocity analyzed from movies acquired for 3 min (1f/2s) in

259 cells treated as in A. Movies were analyzed using Image J manual tracking plug-in. (C) Quantification of relative
260 distribution of mitochondria (#) to the geometrical cell center in cells treated as in A (D) Quantification of
261 mitochondria aspect ratio (length/width) in cells treated as in A (n = 100-120 mitochondria from 4 independent
262 experiments). (E) Quantification of mitochondria fusion using mitoDendra expression in cells treated as in A.
263 (F) Quantification of mitochondrial displacement velocity analyzed from movies acquired for 3 min (1f/2s) in
264 cells treated with tubacin (20 μ M). Movies were analyzed using Image J manual tracking plug-in (125-150
265 mitochondria/10-12 cells from 3 independent experiments). (G) Quantification of relative distribution of
266 mitochondria (#) to the geometrical cell center in cells treated with tubacin (20 μ M). (H) Quantification of
267 mitochondria aspect ratio (length/width) in cells treated with tubacin (20 μ M). (I) Quantification of mitochondria
268 fusion using mitoDendra expression in cells treated with tubacin or control vehicle for 6 h. (G,H and I) n= 125-
269 150 mitochondria from 3-4 independent experiments. (J,K) Heatmap representation of changes in lipid classes
270 in MFN2 KO MEFs treated with vehicle control or TSA (10 nM). (L) Phospholipid synthesis and transfer
271 between ER and mitochondria in WT and Mfn2 KO MEFs treated with vehicle control or TSA (10 nM) for 6 h.
272 Incorporation of 3 H-Ser into 3 H-PtdSer (PS) and (H) 3 H-PtdEtn (PE) after 2 h and 4 h expressed as % of the
273 average value measured in the controls. Cer: ceramide, dhcer: dihydroceramide, SM: sphingomyelin, dhSM:
274 dehydrosphingomyelin, GM3: monosialodihexosylganglioside. BMP: Bis(monoacylglycerol)phosphate, Acyl-
275 PG, acylated phosphatidylglycerol, LPC: Lysophosphatidylcholine, LPCe: Lysophosphatidylcholine
276 plasmalogen, LPE: Lysophosphatidylethanolamine, LPEp: Lysophosphatidylethanolamine plasmalogen; FC:
277 free cholesterol, CE: cholesteryl esters; PA: phosphatidic acid; PC: Phosphatidylcholine; PCe
278 Phosphatidylcholine plasmalogen; PE: Phosphatidylethanolamine; PEp: Phosphatidylethanolamine
279 plasmalogen; PS: Phosphatidylserine; PI: Phosphatidylinositol; PG: Phosphatidylglycerol. * p<0.05; ** p<0.01;
280 *** p<0.001; ns non-significant by Kruskal-Wallis test. Data are expressed as median with interquartile range.

281

282 ***MFN2 regulates α -tubulin acetylation by recruiting ATAT1 at sites of mitochondrial contacts*** 283 ***with MTs***

284 We began to investigate the mechanisms underlying MFN2 regulation of acetylated α -
285 tubulin by measuring levels and localization of ATAT1 and HDAC6 in Mfn2 KO cells. HDAC6
286 expression was three-fold higher in these cells, in contrast to ATAT1 levels, which remained
287 unaffected (Fig. S4A,B). Loss of MFN2 expression did not affect the percentage of cells in mitosis
288 either (Fig. S4C,D). However, when intracellular membranes were subjected to crude fractionation
289 to isolate the cytosolic from the nuclear and ER fractions, unlike HDAC6 which remained mostly
290 cytosolic, ATAT1 appeared in the cytosolic and in the nuclear/ER portion in WT cells but re-
291 distributed more prominently to the nuclear/ER fraction in Mfn2 KO cells (Fig. S4E-G).


292 Accordingly, co-localization of endogenous ATAT1 with the ER appeared to be increased in Mfn2
293 KO cells compared to WT cells (Fig. S4H-J).

294 We hypothesized that MFN2 may negatively regulate ATAT1 association with the ER by
295 localizing ATAT1 to mitochondria outer membranes, and that this localization may facilitate the
296 access of ATAT1 to openings of the MT lattice at sites of mitochondria contacts with MTs. High
297 resolution confocal microscopy of endogenous proteins revealed punctuate localization of ATAT1
298 to mitochondria membranes or MFN2, and this co-localization was lost in cells deprived of MFN2
299 expression (Fig. 3A-F). Localization of ATAT1 to mitochondria was likely to be dependent on the
300 association of MFN2 with an ATAT1 N-terminal fragment (1-242) inclusive of its catalytic
301 domain, as demonstrated by the *in situ* validation of this interaction using the proximity ligation
302 assay (Fig. 3G,H) and conventional pull down analyses from whole cell lysates using full length
303 or C-terminally truncated versions of ATAT1 (Fig. 3I-K).

304 Altogether, our data demonstrate that ATAT1 associates with mitochondria and that this
305 localization is dependent on the binding of the catalytic domain of ATAT1 with MFN2.

306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322

323



324 **Figure 3. MFN2 localizes the ATAT1 to mitochondria outer membranes in MEFs.** (A) Airyscan confocal
 325 analysis of mitochondria (TOMM20) and ATAT1 in WT and Mfn2 KO MEFs. Scale bar, 5 μ m. (B)
 326 Quantification of localization of ATAT1 at mitochondria as in (A) by Mander's correlation coefficient. (C) Line

327 scan analysis of mitochondria and ATAT1 localization from selected regions in (A). Lines are shown as white
328 bars in (A). (D) Airyscan confocal analysis of ATAT1 and MFN2 localization in WT and Mfn2 KO MEFs. Scale
329 bar, 5 μ m. (E) Quantification of localization of ATAT1 and MFN2 as in (D) by Mander's correlation coefficient.
330 (F) Line scan analysis of MFN2 and ATAT1 localization from selected regions in (D). Lines are shown as white
331 bars in (D). (G) Immunofluorescence analysis of MFN2 and ATAT1 PLA signal in WT and Mfn2 KO MEFs.
332 Scale bar, 10 μ m. (H) Quantification of PLA puncta per cell in WT and Mfn2 KO MEFs. n = 50-55 cells from 3
333 independent experiments. (I) Interaction between ATAT1 and MFN2 was detected by immunoprecipitation (IP)
334 followed by immunoblot analysis with the indicated antibodies (upper panel). Similarly, interaction between
335 endogenous ATAT1 and transfected Myc-MFN2 WT was detected in HEK293T cells (lower panel). (J)
336 HEK293T cells were co-transfected with Myc-MFN2 WT and Flag-ATAT1 WT or Flag-ATAT1 (1-242) or
337 Flag-ATAT1 (1-286). Interaction between MFN2 and ATAT1 WT or mutants was detected by co-
338 immunoprecipitation followed by immunoblot analysis with the indicated antibodies. (K) Normalized MFN2 to
339 ATAT1 signal ratio from (J) was plotted. Data are expressed as median with interquartile range. n = 35-50 cells
340 from 3-4 independent experiments. * p<0.05; **** p<0.001; ns non-significant by Mann-Whitney U test (3B,E
341 and H) and Kruskal-Wallis test (3K).

342

343 ***Loss of acetylated tubulin may underlie CMT2A disease***

344 Most MFN2 CMT mutations are missense, and all produce a dominant inheritance pattern,
345 suggesting that mutations in MFN2 lead to either a gain of function or haploinsufficiency [59, 60].
346 Furthermore, recent work supports the notion that restoring MFN1:MFN2 balance by increasing
347 levels of its homologous protein MFN1 is a potential therapeutic approach for CMT2A [46]. The
348 reason for this compensation is unclear, although both MFN2 and MFN1 have been implicated in
349 mitochondria fusion. To determine the involvement of MFN2-dependent regulation of tubulin
350 acetylation in CMT2A disease we investigated whether: 1) mutations in MFN2 affect the
351 interaction with ATAT1 and/or fail to restore normal acetylated tubulin levels in Mfn2 KO cells;
352 2) MFN1 compensates for loss of MFN2 by restoring tubulin acetylation in Mfn2 KO cells; 3) loss
353 of acetylated tubulin by MFN2 depletion is conserved in sensory neurons and sufficient to induce
354 axonal fragmentation, a phenotype associated to axonal forms of CMT disease including CMT2A.

355 We found that MFN2 R94W and T105M, two of the most common N-terminal CMT
356 mutations in MFN2 [61-63] bind to ATAT1 with higher affinity than WT MFN2 (Fig. 4A-C). In
357 addition, while immunofluorescence analysis showed significant higher co-localization of
358 endogenous ATAT1 only with the transfected T105M mutant (Fig. 4D,E), both mutations failed
359 to rescue normal acetylated tubulin levels when expressed in Mfn2 KO cells (Fig. 4F,G). This

360 result was in contrast with ectopic expression of MFN1, which was able to compensate for loss of
361 MFN2 on acetylated tubulin levels in Mfn2 KO cells (Fig. 4H,I).

362 A complex between miro/Milton (TRAK) and MFN2 has been previously shown, and miro
363 has been implicated in regulating MFN2-dependent mitochondrial fusion in response to
364 mitochondrial Ca²⁺ concentration [43]. We tested whether also ATAT1 interacted with miro and/or
365 kinesin heavy chain (Kif5c) and determined the potential effects of mutant MFN2 on the formation
366 of these complexes. We found that ectopic ATAT1 co-immunoprecipitated with both endogenous
367 miro2 and kif5c and that ectopic expression of mutant MFN2 R94W or T105M significantly
368 lowered the affinity of these bindings (Fig. 4J-M). Taken together, these data demonstrate that
369 regulation of acetylated tubulin is an activity shared by MFN1 and that loss of acetylated tubulin
370 may play a primary role in CMT2A *via* the sequestering effect of MFN2 mutations on ATAT1
371 binding.

372 These observations became particularly meaningful when we tested the consequences of
373 loss of MFN2 in sensory neurons and the effects of HDAC6 inhibition on these phenotypes. By
374 analogy with Mfn2 KO cells, silencing of MFN2 expression reduced acetylated tubulin levels both
375 in adult mouse DRG neurons grown in culture and in cell bodies of somatosensory neurons of third
376 instar stage *Drosophila* larvae (Fig. 5A-D). Similar to Mfn2 KO MEFs, we observed localization
377 of endogenous ATAT1 and MFN2 in DRG neurons (Fig. S5A-C) and significant reduction in the
378 extent of ATAT1 localization to mitochondrial membranes in neurons silenced for Mfn2
379 expression in both proximal and distal portion of the axon (Fig. S5D-F). Importantly, cultured
380 sensory neurons deprived of MFN2 acquired a dying-back degeneration phenotype starting from
381 distal regions of the axon, as indicated by the appearance of retraction bulbs at the onset of axonal
382 fragmentation (Fig. 5E and F). We observed that loss of acetylated tubulin preceded axonal
383 degeneration in DRG neurons deprived of MFN2 for shorter times (Fig. S5G-J) and that HDAC6
384 inhibition, which significantly rescued normal acetylated tubulin levels in Mfn2 KD neurons,
385 prevented both retraction bulb formation and axonal degeneration in neurons deprived of MFN2,
386 while having only negligible effects on WT controls (Fig. 5G-I).

387 These findings indicated that MFN2 dependent recruitment of ATAT1 to sites of
388 mitochondrial contacts with MTs is conserved in sensory neurons and required for axonal integrity
389 by maintaining normal levels of MT acetylation. Taking consideration of our functional data in
390 MEF cells, and consistent with previous observations in cellular models of CMT2 caused by

391 MFN2 mutations, these results also suggest that distal axonal degeneration caused by mutant
392 MFN2 predominantly depends on loss of acetylated tubulin, which affects mitochondrial motility
393 and distribution, but not on loss of fusion or functional mitochondria/ER tethering.

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420


421

422

423

424

Figure 4



425 **Figure 4. Regulation of α -tubulin acetylation by MFN2 is affected by MFN2 mutations and shared by**
 426 **MFN1.** (A) HEK293T cells were co-transfected with Flag-ATAT1 and Myc-MFN2 WT or Myc-MFN2 R94W.
 427 (B) HEK293T cells were co-transfected with Flag-ATAT1 and Myc-MFN2 WT or Myc-MFN2 T105M.
 428 Interaction between ATAT1 WT and MFN2 WT or mutants was detected by immunoprecipitation (IP) followed

429 by immunoblot (IB) with the indicated antibodies. (C) The ratio of the MFN2 signal to the ATAT1 signal from
430 (A and B) was plotted. (D) Immunofluorescence analysis of overexpression of Myc-MFN2 WT, Myc-MFN2
431 R94W, Myc-MFN2 T105M in WT MEF cells (n=25-30 cells). (E) Mander's coefficient analysis for WT MEF
432 cells co transfected with Myc-MFN2 WT, Myc-MFN2 R94W and Myc-MFN2 T105M. (F) representative
433 immunoblot of acetylated tubulin levels in Mfn2 KO cells co-transfected with Myc-MFN2 WT, Myc-MFN2
434 R94W and Myc-MFN2 T105M. (G) Quantification of acetylated tubulin levels expressed as % of control levels
435 from 3 independent experiments as in F. (H) Representative immunoblot of acetylated tubulin levels in MFN1
436 overexpressing WT and Mfn2 KO cells. (I) Quantification of acetylated tubulin levels expressed as % of control
437 levels from 4 independent experiments as in H. (J) Interaction between ATAT1 or its truncated mutants (1-242;
438 1-286) and endogenous Miro2 or Kif5c was detected in HEK293T cells transfected with Flag-ATAT1 WT or its
439 truncated mutants. (K) The ratio of the Miro2 and Kif5c signal to the ATAT1 signal from (J) was plotted. (L)
440 Interaction between Flag-ATA1 and endogenous Miro2 or Kif5c was detected in HEK293T cells in presence or
441 absence of Myc-MFN2 WT, Myc-MFN2 R94W and Myc-MFN2 T105M. (M) The ratio of the Miro2 and Kif5c
442 signal to the ATAT1 signal from (L) is plotted. Data are expressed as median with interquartile range. n= 3-4
443 independent experiments. * $p \leq 0.05$, ** $p < 0.01$; ns non-significant by Kruskal-Wallis test. Scale bar, 10 μm .

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461


462

463

464

465

Figure 5



466 **Figure 5. MFN2 regulates α -tubulin acetylation in sensory neurons in vitro and in vivo and this activity is**
 467 **required for axonal integrity.** (A) Representative immunoblot of MFN2, acetylated (Acet) and detyrosinated

468 tubulin (deTyr) levels in adult DRG neurons (14 DIV) silenced of Mfn2 expression at 7 DIV. GAPDH, loading
469 control. (B) Quantification of acetylated tubulin relative in MFN2 depleted DRG neurons relative to control
470 neurons infected with shNC (non-coding shRNA). (C) Multi-dendritic neuron driver 109(2)80 Gal4 driver was
471 used to label somatosensory neurons (CD8-GFP) and knockdown (KD) Marf in *Drosophila* larval
472 somatosensory neurons. Acetylated tubulin levels were measured in the cell bodies as demarcated in the images.
473 Confocal stacks spanning the cell body were examined to reveal acetylated tubulin staining in cell bodies distinct
474 from nearby epidermis. To quantify levels of acetylated tubulin staining in cell bodies, images were sub-stacked
475 for each cell body (average intensity z-projection) and blinded. Mean gray value was measured and normalized
476 against the background level of acetylated tubulin staining (see methods for further information). (D)
477 Quantification of acetylated tubulin protein expression in cell bodies after Marf knockdown in somatosensory
478 neurons in larvae. Two different strategies were used, Marf KD-1 (BL 67158) and KD-2 (BL 31157). (E) Images
479 of representative fields showing dissociated adult DRG neurons (14 DIV) treated as in A, fixed and
480 immunostained with mouse anti-neurofilament (2H3-s) antibody. (F) Quantification of number of retraction
481 bulbs per field and degree of axonal degeneration. The area occupied by the axons (total axonal area) and
482 degenerating axons (fragmented axonal area) was measured in the same field from images in WT and MFN2
483 KD DRG neurons. Degeneration index was calculated as the ratio between fragmented axonal area and total
484 axonal area. (G) Representative immunoblot of MFN2, acetylated tubulin (Acet) levels in control (shNC) and
485 MFN2 (shMFN2) silenced DRG neurons incubated with 10 μ M of the HDAC6 inhibitor TSA or vehicle control
486 for 6 h prior to lysis. GAPDH, loading control. (H) Representative immunofluorescence images of DRG neurons
487 treated as in G. (I) Quantification of number of retraction bulbs per field and degree of axonal degeneration in
488 DRG neurons treated as in G prior to fixation and staining. Data are represented as median and interquartile
489 range from 3 independent experiments. * $p < 0.05$; ** $p < 0.01$, *** $p < 0.001$ by Mann-Whitney U test (B, D and
490 F) and Kruskal-Wallis test (I). Scale bars, 5 μ m (C); 50 μ m (H).

491

492 Discussion

493 MFN2 mutations in CMT2A disrupt the fusion [64] of mitochondria and compromise ER-
494 mitochondrial interactions [34, 47]. However, while certain CMT2A mutant forms of MFN2
495 impair mitochondrial fusion and/or functional mitochondria/ER tethering, others do not affect
496 either function [64], casting doubt on the implication of these MFN2 activities in the etiology of
497 CMT2.

498 In this study we report that MFN2 is a regulator of α -tubulin acetylation and MT dynamics,
499 and that in Mfn2 KO MEFs rescuing α -tubulin acetylation levels by pharmacological inhibition
500 of HDAC6 corrects defects in MT dynamics and mitochondrial motility, some MAM function
501 but not MAM integrity or mitochondrial fusion. We also show that regulation of tubulin

502 acetylation by MFN2 occurs through MFN2-mediated recruitment of ATAT1 to outer
503 mitochondrial membranes, an activity conserved in sensory neurons, critical in the induction of
504 axonal degeneration by MFN2 loss of function and impaired in two MFN2 mutants associated
505 with CMT2A. Interestingly, the binding of MFN2 to ATAT1 is dependent on the N-terminal
506 catalytic domain of ATAT1 and the same domain is also necessary for the association of
507 ATAT1 with kinesin-1 but not with miro, a Rho-GTPase implicated in the regulation of
508 mitochondrial transport by linking mitochondria outer membranes to kinesin and dynein motors
509 [65, 66]. Conversely, both MFN2 R94W and T105M mutants disrupt the binding of ATAT1 with
510 either miro or kinesin-1, suggesting that while ATAT1 binding to miro may not depend on kinesin,
511 the formation of a stable ATAT1/miro/kinesin-1 complex relies on functional MFN2. Based on
512 these observations, we propose that, in analogy to axonal vesicles [21], mitochondria contacts with
513 MTs are hotspots of tubulin acetylation and that this function is impaired in CMT2 disease caused
514 by MFN2 mutations. Specifically, we suggest that mutant MFN2 R94W or T105M drive axonal
515 degeneration by disrupting the ability of mitochondria to release the ATAT1 at specific sites on
516 axonal MTs, leading to an imbalance in tubulin acetylation and disrupted mitochondrial transport.
517 Our findings also provide evidence that the release of ATAT1 by MFN2 depends on the
518 formation of a stable ATAT1/miro/kinesin-1 complex, which may be necessary to allow
519 discharge of ATAT1 at putative entry sites into the MT lattice. This is in line with the
520 observation that motors can leave marks in the MT shaft by inducing breaks in the lattice and
521 promote MT self-repair [48, 50, 51]. Further work is required to understand the rules of site
522 selection and whether a break in the MT lattice is sufficient to induce ATAT1 release from
523 MFN2 through a putative conformational change in the motor complex.

524 By combining our observations in Mfn2 KO MEFs and KD sensory neurons, we propose
525 that axonal degeneration caused by MFN2 loss of function mutations may not depend on
526 impaired mitochondrial fusion or functional mitochondria/ER tethering, but rather loss of
527 MFN2-dependent regulation of mitochondrial transport by interfering with tubulin acetylation
528 at sites of mitochondria and MT contact. Our interpretation is consistent with a pathogenic role
529 for disrupted mitochondrial transport in neuropathies and a key role for tubulin acetylation in
530 mitochondrial dynamics. Indeed, multiple studies report that axonal degeneration precedes cell
531 body death in several peripheral neuropathies, including CMT disease. Mitochondria are the
532 principal mediators of ATP production and Ca²⁺ buffering, and they actively distribute to areas of

533 high energy demand and Ca^{2+} flux within the axon [43, 44]. A general defect in the ability of
534 mitochondria to translocate to these sites would be expected to lead to preferential degeneration of
535 long axons that frequently experience fluctuations in ATP and Ca^{2+} levels.

536 Several lines of evidence further support a role for perturbation of acetylated tubulin levels
537 in CMT2A: 1) mutant MFN2 (MFN2R94Q) knock-in mice lack acetylated tubulin in distal axons
538 of their long peripheral nerves [29]; 2) HDAC6 inhibition has been reported to be a promising
539 therapeutical approach in several toxic and familial peripheral neuropathies, including CMT2A
540 [29]; 3) the formin INF2, mutations of which cause dominant intermediate CMT in association
541 with FSGS [67], is a positive regulator of tubulin acetylation by modulating ATAT1 transcription.
542 We note, however, that HDAC6 deacetylates additional lysine residues of α - and β -tubulin and has
543 multiple substrates in addition to tubulin, casting doubt on the specificity of this approach.
544 Conversely, tubulin is the only known substrate for ATAT1. In addition, the structure of ATAT1
545 provides a unique scaffold for designing small molecule modulators of tubulin acetylation for
546 therapeutic use [68]. In particular, the identification of ATAT1 mutations that decrease or increase
547 ATAT1 activity suggests that small molecule compounds could be identified to increase or
548 decrease ATAT1 activity to stabilize or destabilize MTs for therapeutic purposes [68]. Taken
549 together, these studies indicate that targeting ATAT1 activity or expression may represent an
550 alternative and more specific therapeutic approach aimed at restoring sensory neuron function in
551 CMT2A and perhaps other related CMT subtypes.

552

553 MATERIALS AND METHODS

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Mouse monoclonal mitofusin-2 (6A8)	Abcam	Ab56889
Rabbit monoclonal mitofusin-2	Abcam	Ab124773
Rabbit polyclonal IQGAP1	Novus Biologicals	NBP1-06529
Rabbit polyclonal HDAC6	Novus Biologicals	NBP1-78981
Rabbit polyclonal ATAT1	Bioss	Bs-9535R
Rabbit monoclonal TOMM20	Abcam	Ab186735

Mouse monoclonal TOMM20	Millipore Sigma	KB061-4F3
Rabbit polyclonal detyrosinated tubulin	Abcam	Ab48389
Rat tyrosinated tubulin, clone YL1/2	Millipore	MAB1864-I
Mouse monoclonal acetylated tubulin	Sigma Aldrich	T6793
Mouse monoclonal DM1A	Sigma Aldrich	T6199
Human anti-tubulin GTP (MB11)	Adipogen	AG-27B-0009-C100
Rabbit polyclonal TTL	Proteintech	13618-1-AP
Mouse monoclonal PDI	Santacruz	SC-74551
Mouse monoclonal anti-c-Myc 9E10 HRP	Santacruz	SC-40 HRP
Mouse monoclonal anti-c-Myc 9E10 Agarose	Santacruz	SC-40 AC
Mouse monoclonal anti-Flag M2 HRP	Sigma Aldrich	A8592
Mouse monoclonal anti-Flag M2 Agarose	Sigma Aldrich	A2220
Chicken polyclonal neurofilament	Aves labs	AB_2313553
Rabbit polyclonal anti-Miro2	Proteintech	11235-1-AP
Rabbit polyclonal anti-Kif5c	Proteintech	25897-1-AP
Mouse monoclonal GAPDH	Abcam	Ab8245
Rabbit polyclonal GAPDH	ThermoFisher	PA1-987
Goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Flour 488-conjugated	ThermoFisher	A11029
Goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Flour 488-conjugated	ThermoFisher	A11034
Goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Flour 546-conjugated	ThermoFisher	A11030
Goat anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Flour 546-conjugated	ThermoFisher	A11035
Goat anti-human IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Flour 568-conjugated	ThermoFisher	A-21090
IRDye® 680RD Goat anti-mouse IgG secondary antibody	LI-COR	926-68070

IRDye® 800CW Goat anti-rabbit IgG secondary antibody	LI-COR	926-32211
IRDye® 680RD Goat anti-rabbit IgG secondary antibody	LI-COR	926-68071
IRDye® 800CW Goat anti-rabbit IgG secondary antibody	LI-COR	926-32211
Bacteria strains		
DH5 alpha	New England Biolabs	C2987I
XL1-Blue	Agilent	200229
Chemicals and Reagents		
Trichostatin A (TSA)	Tocris	#1406
Tubacin	Millipore Sigma	SML0065
Mitotracker Red CMXRos	Thermofisher	M7512
DMEM	Gibco	11995-065
Neurobasal	Thermofisher	110349
Fetal bovine serum	HyClone	SH30071.03
Bovine calf serum	Thermofisher	26170043
B-27 supplement (50x)	Thermofisher	7504044
Penicillin-streptomycin	Thermofisher	15140163
10x HBSS	Thermofisher	14065056
Cytosine β -D-arabinofuranoside hydrochloride (AraC)	Millipore Sigma	C6645
Collagenase	Millipore Sigma	C0130
Trypsin 0.05% EDTA	Thermofisher	25300054
GlutaMAX Supplement	Thermofisher	35050061
Poly-D-Lysine	Sigma Aldrich	P1149
Laminin	Sigma Aldrich	11243217001
Laemlli SDS sample buffer, reducing	Thermofisher	J60015-AD

NuPAGE MOPS SDS Running buffer	ThermoFisher	NP0001
Fluoromount-G	Southern Biotech	0100-01
32% PFA	EMS	15714-S
DreamFect™ Gold transfection reagent	OZ Bioscience	DG80500
c-Myc Peptide	Sigma Aldrich	M2435
Flag peptide	Sigma Aldrich	F3290
Critical commercial assays		
DuoLink PLA In Situ Red starter mouse/rabbit kit	Sigma-Aldrich	DUO92101
Experimental models: Organisms/strains		
<i>UAS-MARF RNAi</i>	Bloomington Stock Center	BL 31157
<i>UAS-MARF miRNA CDS</i>	Bloomington Stock Center	BL 67158
Mouse: C57BL/6J	Charles River Laboratories	RRID:IMSR_CRL: 027
Recombinant DNA		
pLKO.1 shMfn2	Sigma Aldrich	TRCN0000080608
pLKO.1 shTTL	Sigma Aldrich	TRCN0000191515
Myc-MFN2 WT	David Chan	NA
Myc-MFN2 R94W	David Chan	NA
Myc-MFN2 T105M	David Chan	NA
Flag-ATAT1 WT	Laurent Ngyuen	NA
Flag-ATAT1 (1-242)	Laurent Ngyuen	NA
Flag-ATAT1 (1-286)	Laurent Ngyuen	NA
Zsgreen-MFN1	Estella Area Gomez	NA
Software		
ImageJ (Fiji)	NIH	RRID:SCR_00228 5

GraphPad Prism	GraphPad	RRID:SCR_002798
Li-COR Image Studio Software	Li-COR	RRID:SCR_015795
Zeiss ZEN	Zeiss	RRID:SCR_013672
Andor iQ3	Oxford Instruments	RRID:SCR_014461
Other		
18 mm No.1 circle coverglass	Carolina	633033
35 mm MatTek dishes	MatTek	P35G-1.5-14-C
NuPAGE Gel	ThermoFisher	NP0316
Nitrocellulose membrane	Fisher	10600011

554

555 **Lead contact and materials availability**

556 Further information and requests for resources and reagents should be directed to and will be
557 fulfilled by the lead contact, Francesca Bartolini (fb2131@columbia.edu).

558

559 **Experimental model and subject details**

560 All protocols and procedures for mice were approved by the Committee on the Ethics of Animal
561 Experiments of Columbia University and according to Guide for the Care and Use of Laboratory
562 Animals of the National Institutes of Health.

563

564 **Cell culture and analyses**

565 WT, Mfn2 KO, Mfn1 KO (kind gifts of Dr. Area-Gomez) and Iqgap1 KO mouse embryonic
566 fibroblast cells were grown in DMEM supplemented with 10% fetal bovine serum. Cells were
567 grown to 80% confluency on acid treated glass coverslips prior to experiment.

568 **Immunofluorescence microscopy and analyses**

569 For immunofluorescence staining of the MT cytoskeleton, cells were fixed in ice cold MetOH for
570 10' prior to rehydration in PBS buffer o/n at 4°C. For all other stainings, cells were fixed in 4%
571 PFA for 15 min and permeabilized with 0.1% Triton X-100 for 5 min at R.T. Cells were then
572 washed in PBS, blocked in 2% FBS and 2% BSA in PBS for 1 h, stained with primary antibodies
573 overnight at 4°C followed by secondary antibodies for 1 h. Mounted samples were observed using
574 a Zeiss LSM 800 confocal microscope equipped with Airyscan module, using a 63x objective
575 (Plan-Apochromat, NA 1.4). Images were acquired and processed using Zen Blue 2.1 software.
576 All images were analyzed by ImageJ software.

577

578 **Western blot analyses**

579 Cells were lysed in Laemmli sample buffer and boiled at 96°C for 5 min. Cell lysates were
580 sonicated with a probe sonicator to shear cellular debris and genomic DNA. Proteins were
581 separated by 10% Bis-Tris gel (Invitrogen) and transferred onto nitrocellulose membrane. After
582 blocking in 5% milk/TBS or BSA/TBS, membranes were incubated with primary antibodies at
583 4°C overnight prior to 1 h incubation with secondary antibodies. Image acquisition was performed
584 with an Odyssey imaging system (LI-COR Biosciences, NE) and analyzed with Odyssey software.

585

586 **Proximity ligation assay (PLA)**

587 PLA assays were carried out using a Duolink *in situ* red starter kit mouse/rabbit kit (Sigma-
588 Aldrich) according to the manufacturer's protocol. The primary antibodies used were mouse anti-
589 MFN2 and rabbit anti-ATAT1 (1:1000 dilution). Images were acquired on a Zeiss LSM
590 800 confocal microscope and analyzed using ImageJ/FIJI. Data were pulled from at least three
591 independent biological repeats.

592

593 **Analysis of mitochondrial morphology, motility and distribution**

594 Mitochondria were labeled using mitotracker Red CMROX according to manufacturer protocol
595 (Thermo Fisher Scientific) and detected by epifluorescence microscope equipped with 60 x
596 objective lens (Olympus IX81) and a monochrome CCD camera (Sensicam QE, Cooke
597 Corporation). Aspect ratio (length/width) were measured using Image J/FIJI. For mitochondrial
598 distribution and displacement velocity mitochondria were live imaged for 3 min at 2 sec/frame at

599 37°C. A customized Mitoplot software (kind gift of Dr. Gregg Gundersen) was used for analyzing
600 mitochondrial distribution. Manual tracking plug-in in ImageJ/FIJI was used to analyze
601 mitochondrial displacement velocity.

602

603 **Microtubule dynamics**

604 Fibroblasts were transfected with pMSCV-puro-tagGFP-C4 α -tubulin plasmid to generate a green
605 fluorescent protein (GFP)-tubulin stably expressing cell line. Live imaging of MT dynamics in
606 transfected cells was performed at 37°C and 5% CO₂ for 5 min (5 s/frame) with a 100× PlanApo
607 objective (numerical aperture 1.45) and an iXon X3 CCD camera (Andor, Belfast, United
608 Kingdom) on a Nikon Eclipse Ti microscope controlled by Nikon's NIS-Elements software
609 (Nikon, Tokyo, Japan). Movies were analyzed by ImageJ using a manual tracking plug-in.

610

611 **Mitodendra**

612 Dendra2 photoconversion and imaging utilized the protocol from Evrogen. Images were acquired
613 with an Olympus spinning disk microscope EC-Plan-Neofluar 40X/1.3 oil. Z-stack acquisitions
614 over-sampled each optical slice twice, and the Zen 2009 image analysis software was used for
615 maximum z-projections. The 488 nm laser line and the 561 nm laser excited Dendra2 in the
616 unconverted state and photo-converted state, respectively. To photo-switch Dendra2, a region was
617 illuminated with the 405 nm line (4% laser power) for 90 bleaching iterations.

618

619 **Lentivirus production**

620 Production of lentiviral particles was conducted using the second-generation packaging system as
621 previously described [69, 70]. In brief, HEK293T cells were co-transfected with lentiviral plasmid
622 shRNA and the packaging vectors pLP1, pLP2, and pLP-VSV-G (Thermo Fisher) using the Ca²⁺
623 phosphate transfection method. At 24, 36, and 48 h after transfection, the virus-containing
624 supernatant was collected, and the lentiviral particles concentrated (800-fold) by
625 ultracentrifugation (100,000 × g at 4 °C for 2 h) prior to aliquoting and storage at -80 °C.

626

627 **MT stability**

628 WT and Mfn2 KO MEFs were incubated at 8 °C for 30 min to induce mild microtubule
629 depolymerization. At the end of the incubation time, cells were gently washed with PEM 1× buffer
630 (85 mM Pipes, pH 6.94, 10 mM EGTA, and 1 mM MgCl₂) twice before extraction with PEM
631 buffer, supplemented with 0.05 % Triton X-100. After 1 min extraction at 8 °C, a matching volume
632 of fixative buffer (ice cold MetOH) was added dropwise to the coverslips, and cells were incubated
633 for another 5 min at -20 °C. Cells were finally washed with PBS 1× and processed for
634 immunofluorescence labeling. All images were analyzed using ImageJ software [71].

635

636 **Analysis of phospholipid synthesis in cultured cells**

637 Both mitochondria and ER play key roles in the synthesis of phosphatidylserine (PtdSer),
638 phosphatidylethanolamine (PtdEtn), and phosphatidylcholine (PtdCho). PtdSer is synthesized in
639 the MAM; it then translocates to mitochondria, where it is converted to PtdEtn; PtdEtn then
640 translocates back to the MAM, to generate PtdCho[72]. To test the effect of MFN2 on phospholipid
641 synthesis mediated by MAM, WT and Mfn2 KO MEF cells were incubated for 2 h with serum-
642 free medium to ensure removal of exogenous lipids. The medium was then replaced with MEM
643 containing 2.5 µCi/ml of ³H-serine for 2, 4 and 6 h. The cells were washed and collected in DPBS,
644 pelleted at 2500 g for 5 min at 4°C, and resuspended in 0.5 ml water, removing a small aliquot for
645 protein quantification. Lipid extraction was done by the Bligh and Dyer method. Briefly, three
646 volumes of chloroform/methanol 2:1 were added to the samples and vortexed. After centrifugation
647 at 8000 g for 5 min, the organic phase was washed twice with two volumes of methanol/water 1:1,
648 and the organic phase was blown to dryness under nitrogen. Dried lipids were resuspended in 60
649 µl of chloroform/methanol 2:1 (v/v) and applied to a TLC plate. Phospholipids were separated
650 using two solvents, composed of petroleum ether/diethyl ether/acetic acid 84:15:1 (v/v/v) and
651 chloroform/methanol/acetic acid/water 60:50:1:4 (v/v/v/v). Development was performed by
652 exposure of the plate to iodine vapor. The spots corresponding to the relevant phospholipids
653 (identified using co-migrating standards) were scraped and counted in a scintillation counter
654 (Packard Tri-Carb 2900TR). Both mitochondria and ER play key roles in the synthesis of
655 phosphatidylserine (PtdSer), phosphatidylethanolamine (PtdEtn), and phosphatidylcholine
656 (PtdCho). PtdSer is synthesized in the MAM; it then translocates to mitochondria, where it is
657 converted to PtdEtn; PtdEtn then translocates back to the MAM, to generate PtdCho [73].
658 Therefore, to test directly the effect of MFN2 mutations on phospholipid synthesis mediated by

659 MAM, we incubated control and Mfn2 KO fibroblasts in medium containing ^3H -serine and
660 measured the incorporation of the label into newly-synthesized ^3H -PtdSer and ^3H -PtdEtn after 2
661 and 4 h.

662

663 **Lipidomics**

664 All samples were collected and treated following recently accepted guidelines for the analysis of
665 human blood plasma and/or serum. Lipids were extracted from equal amounts of material-(0.2
666 ml/sample) by a chloroform-methanol extraction method. Three comprehensive panels, scanning
667 for either positive lipids, negative lipids or neutral lipids (under positive mode), were analyzed.
668 Equal amounts of internal standards with known concentrations were spiked into each extract.
669 Each standard was later used to calculate the concentrations of corresponding lipid classes by first
670 calculating ratio between measured intensities of a lipid species and that of corresponding internal
671 standard multiplied by the known concentration of the internal standard. Samples were analyzed
672 using a 6490 Triple Quadrupole LC/MS system (Agilent Technologies, Santa Clara, CA).
673 Cholesterol and cholesterol esters were separated with normal-phase HPLC using an Agilent
674 Zorbax Rx-Sil column (inner diameter 2.1 Å~ 100 mm) under the following conditions: mobile
675 phase A (chloroform:methanol:1 M ammonium hydroxide, 89.9:10:0.1, v/v/v) and mobile phase
676 B (chloroform:methanol:water: ammonium hydroxide, 55:39.9:5:0.1, v/v/v/v); 95% A for 2 min,
677 linear gradient to 30% A over 18 min and held for 3 min, and linear gradient to 95% A over 2 min
678 and held for 6 min.

INTERNAL STANDARD	Corresponding Lipid Class	Concentration (ug/ul)
IS AcylPG 14:0-28:0	Acyl PG, NAPE, NAPS	0.046799614
IS BMP 28:0	BMP	0.015298133
IS CE C17	CE	78.59098931
IS Cer C17:0	Cer, dhCer	0.758320608
IS Chol d7 b	Free Cholesterol	63.78791732

IS DG 4ME	diacylglycerols	0.640874053
IS dhSM d18:0/12:0	dihydrosphingomyelins	2.579623778
IS DMPC	AC	12.34642208
IS GalCer d18:1/12:0	MhCer	1.039897431
IS LacCer d18:1/12:0	LacCer	0.259594347
IS LPC 13:0	LPC	12.34642208
IS LPE 14:0	LPE	0.098349468
IS LPI 13:0	LPI	0.07642123
IS MG C17	MG	0.242952978
IS PA 28:0	PA	0.068072997
IS PC 28:0	PC	12.34642208
IS PE 25:0	PE	8.839285714
IS PG 12:0/13:0	PG	0.446428571
IS PI 12:0/13:0	PI	2.232142857
IS PS 28:0	PS	11.92531331
IS SM d18:1/12:0	SM	13.39285714
IS Sulf d18:1/12:0	Sulf	0.225924621
IS TG 50:0 d5	TG	0.498018035

679

680

681 **Cellular fractionation**

682 WT and Mfn2 KO fibroblasts were cultured on 15 cm petri dishes. Buffer A (10mM HEPES, 1.5
683 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, 0.05% NP40, pH 7.9) was prepared freshly and protease
684 and phosphatase inhibitors were added. Cells were scraped thoroughly using buffer A and left on
685 ice for 10 min. Samples were centrifuged at 3000 rpm for 10 min at 4°C and supernatants stored
686 on ice. Pellets were resuspended in buffer B (5 mM HEPES, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5
687 mM DTT, 26% Glycerol (v/v), pH 7.9) and added 4.6 M NaCl. Homogenize with 20 full stroke of
688 Dounce homogenizer on ice and leave it on ice for 30 min.

689

690 **Isolation of adult DRG neurons**

691 DRG were dissected from 8- to 10-wk-old C57BL/6J mice in cold Hank's balanced salt solution
692 (HBSS) (Life Technologies) or Dulbecco's Modified Eagle's medium (Life Technologies) and
693 dissociated in 1 mg/mL Collagenase A for 1 h at 37 °C, followed by 0.05% trypsin (Life
694 Technologies) digestion for 3 to 5 min at 37 °C and washed with Neurobasal medium (Invitrogen)
695 supplemented with 2% B-27 (Invitrogen), 0.5 mM glutamine (Invitrogen), fetal bovine serum
696 (FBS), and 100 U/mL penicillin-streptomycin. DRG neurons were then triturated by repeated
697 gentle pipetting until no clump was visible, and neuronal bodies were resuspended in Neurobasal
698 medium with FBS prior to plating onto 12 well plates (over 18 mm coverslips) that had been coated
699 overnight with 100 µg/ mL poly-D-lysine at 37 °C and for 1 h at 37 °C with 10 µg/mL laminin
700 (Life Technologies). After 30 min, Neurobasal medium, without FBS, was added to the plate. At
701 4 DIV, at least 30% of media was changed and 10 µM AraC was added to media every 4 d.

702

703 **Degeneration index in DRG neurons**

704 As reported previously [69], images of an average of 10 random fields of dissociated adult DRG
705 neurons fixed and immunostained with mouse anti-neurofilament antibody were acquired using a
706 20× objective lens (Olympus IX81) coupled to a monochrome CCD camera (Sensicam QE; Cooke
707 Corporation). To quantify axonal degeneration, the areas occupied by the axons (total axonal area)
708 and degenerating axons (fragmented axonal area) were measured in the same field from images of
709 DRG neurons. Images were automatically thresholded (global threshold) using a default auto
710 threshold method, binarized, and the fragmented axonal area measured by using the particle

711 analyzer module of ImageJ (size of small fragments = 20 to 10,000 pixels). Degeneration index
712 was calculated as the ratio between the fragmented axonal area and the total axonal area.

713

714 **Immunolabeling of *Drosophila* larvae**

715 Immunolabeling of *Drosophila* larvae was performed largely as described previously [74]. Briefly,
716 late third instar larvae were dissected in 1 × PBS, fixed in 4% paraformaldehyde (PFA, Electron
717 Microscopy Sciences) in 1 × PBS for 15 min, washed three times in 1 × PBS + 0.3% Triton X-100
718 (PBS-TX), and blocked for 1h at room temperature (RT) or overnight at 4 °C in 5% normal donkey
719 serum (NDS) in PBS-TX (Jackson Immunoresearch). Primary antibodies were chicken anti-GFP
720 (1:1000; Abcam) and acetylated alpha-tubulin (1:400; Sigma Aldrich) diluted in 5% NDS in PBS-
721 TX. The tissue was incubated overnight in primary antibodies at 4 °C and then washed in PBS-TX
722 for 3 × 15 min at RT. Species-specific, fluorophore-conjugated secondary antibodies (Jackson
723 ImmunoResearch) were used at 1:1000 in 5% NDS in PBS-TX and incubated overnight 4 °C.
724 Tissue was washed in PBS-TX for 3 × 15 min. Immunolabeled tissue was mounted on poly-L-
725 lysine coated coverslips, dehydrated 5 minutes each in an ascending ethanol series (30, 50, 70, 95,
726 2 × 100%), cleared in xylenes (2 × 10 min), and mounted in DPX (Fluka).

727

728 **Imaging and quantification of *Drosophila* sensory neurons**

729 Images of somatosensory neurons from *Drosophila* larvae were acquired using a Yokogawa CSU-
730 W1 SoRa mounted on a Zeiss Axio Observer using a 60x 1.46 NA Alpha Plan-Apochromat oil
731 objective and a 4x magnification changer. Acquisitions included the cell body, axon, and dendrites
732 of somatosensory neurons. Subsequent image analysis was performed using Fiji. Using the md
733 neurons (109(80)2-Gal4, UAS-CD8-GFP) as reference, sub stacks covering the z-depth of each
734 cell body were cropped and blinded for subsequent analysis. Additionally, 2-3 areas (300 x 300
735 px) devoid of neurons in the same image were selected to measure background levels of acetylated
736 tubulin in each image and used to normalize the levels in the cell body. To measure acetylated
737 tubulin levels in the cell bodies, cell bodies were selected using the polygon selection tool, and the
738 area outside the cell body was cleared to avoid including acetylated tubulin staining surrounding
739 the cell body in the subsequent quantification. Processed z-stacks of cell bodies were z-projected
740 using average intensity. The mean gray value was measured and normalized against background

741 levels of acetylated tubulin quantified in the same image. Raw images were used for quantification.
742 Represented images shown in Fig. 5C were deconvolved using Microvolution (20 iterations).

743

744 **Co-immunoprecipitation assay**

745 HEK293T cells were cultured in Dulbecco's modified Eagle's medium plus 10% fetal bovine
746 serum (FBS), penicillin–streptomycin (1%) and L-glutamine (1%). Transient transfections were
747 performed using DreamFect™Gold transfection reagent (Oz Biosciences SAS, Marseille, FR) in
748 accordance with the manufacturer's protocols. HEK293T cells were lysed in RIPA buffer (50 mM
749 Tris-HCl at pH 7.6, 150 mM NaCl, 0.5% sodium deoxycholic, 5 mM EDTA, 0.1% SDS, 100 mM
750 NaF, 2 mM NaPPi, 1% NP-40) supplemented with protease and phosphatase inhibitors, then
751 centrifuged at 13,000 rpm for 30 min at 4 °C and the resulting supernatants were subjected to
752 Bradford protein assay (Bio-Rad, Hercules, California, USA) for measuring total protein
753 concentration. Immunoprecipitations were performed on 1mg of whole cell extracts by using anti-
754 c-Myc agarose conjugated or anti-Flag M2 agarose (1–2 µg) for 2 h at 4 °C with rotation. c-Myc
755 peptide or Flag-peptide (0,1 mg/ml) was used as a control. The immunoprecipitates were then
756 washed five times with RIPA buffer, resuspended in sample loading buffer, boiled for 5 min,
757 resolved in sodium dodecyl sulphate–polyacrylamide gel electrophoresis (SDS-PAGE), and then
758 subjected to immunoblot analysis.

759

760 **Quantification and statistical analysis**

761 Data are shown as median with interquartile range from at least 3 independent experiments and
762 figures are generated by GraphPad Prism. Image analysis was performed by ImageJ (Fiji).
763 Statistical analysis between two groups was performed Mann-Whitney *U* test and among 3 or more
764 groups was performed using the Kruskal-Wallis with Dunn's multiple comparisons test. Data are
765 shown as means \pm SEM, and statistical significance was analyzed by student's *t* test (Table1) and
766 two-way ANOVA with Dunnett's multiple comparison (Table S1 and S2).

767

768 **Acknowledgements**

769 This study was funded by a TIGER Grant from the Taub Institute for Research on Alzheimer's
770 Disease and the Aging Brain at Columbia University to F.B., the RF1AG050658 (NIH/NIA)
771 and R21NS120076 (NIH/NINDS) awards to F.B. We are grateful to Gregg G. Gundersen for

772 stimulating discussions and access to his microscopes, and to Laurent Nguyen for sharing his
773 ATAT1 constructs. Figures were prepared using PowerPoint and BioRender.

774

775 References

- 776 1. Goodson, H.V. and E.M. Jonasson, *Microtubules and Microtubule-Associated Proteins*.
777 Cold Spring Harb Perspect Biol, 2018. **10**(6).
- 778 2. Kapitein, L.C. and C.C. Hoogenraad, *Building the Neuronal Microtubule Cytoskeleton*.
779 Neuron, 2015. **87**(3): p. 492-506.
- 780 3. Baas, P.W., et al., *Polarity orientation of microtubules in hippocampal neurons: uniformity*
781 *in the axon and nonuniformity in the dendrite*. Proc Natl Acad Sci U S A, 1988. **85**(21): p.
782 8335-9.
- 783 4. Goldstein, L.S. and Z. Yang, *Microtubule-based transport systems in neurons: the roles of*
784 *kinesins and dyneins*. Annu Rev Neurosci, 2000. **23**: p. 39-71.
- 785 5. Magiera, M.M., et al., *Tubulin Posttranslational Modifications and Emerging Links to*
786 *Human Disease*. Cell, 2018. **173**(6): p. 1323-1327.
- 787 6. Pero, M.E., F. Chowdhury, and F. Bartolini, *Role of tubulin post-translational*
788 *modifications in peripheral neuropathy*. Exp Neurol, 2023. **360**: p. 114274.
- 789 7. Portran, D., et al., *Tubulin acetylation protects long-lived microtubules against mechanical*
790 *ageing*. Nat Cell Biol, 2017. **19**(4): p. 391-398.
- 791 8. Eshun-Wilson, L., et al., *Effects of alpha-tubulin acetylation on microtubule structure and*
792 *stability*. Proc Natl Acad Sci U S A, 2019. **116**(21): p. 10366-10371.
- 793 9. Janke, C. and G. Montagnac, *Causes and Consequences of Microtubule Acetylation*. Curr
794 Biol, 2017. **27**(23): p. R1287-R1292.
- 795 10. Barlan, K. and V.I. Gelfand, *Intracellular transport: ER and mitochondria meet and greet*
796 *along designated tracks*. Curr Biol, 2010. **20**(19): p. R845-7.
- 797 11. Rowland, A.A. and G.K. Voeltz, *Endoplasmic reticulum-mitochondria contacts: function*
798 *of the junction*. Nat Rev Mol Cell Biol, 2012. **13**(10): p. 607-25.
- 799 12. Tran, A.D., et al., *HDAC6 deacetylation of tubulin modulates dynamics of cellular*
800 *adhesions*. J Cell Sci, 2007. **120**(Pt 8): p. 1469-79.
- 801 13. Valenzuela-Fernandez, A., et al., *HDAC6: a key regulator of cytoskeleton, cell migration*
802 *and cell-cell interactions*. Trends Cell Biol, 2008. **18**(6): p. 291-7.
- 803 14. Akella, J.S., et al., *MEC-17 is an alpha-tubulin acetyltransferase*. Nature, 2010. **467**(7312):
804 p. 218-22.
- 805 15. Shida, T., et al., *The major alpha-tubulin K40 acetyltransferase alphaTAT1 promotes rapid*
806 *ciliogenesis and efficient mechanosensation*. Proc Natl Acad Sci U S A, 2010. **107**(50): p.
807 21517-22.
- 808 16. L'Hernault, S.W. and J.L. Rosenbaum, *Chlamydomonas alpha-tubulin is*
809 *posttranslationally modified by acetylation on the epsilon-amino group of a lysine*.
810 Biochemistry, 1985. **24**(2): p. 473-8.
- 811 17. LeDizet, M. and G. Piperno, *Identification of an acetylation site of Chlamydomonas alpha-*
812 *tubulin*. Proc Natl Acad Sci U S A, 1987. **84**(16): p. 5720-4.
- 813 18. Schaedel, L., et al., *Microtubules self-repair in response to mechanical stress*. Nat Mater,
814 2015. **14**(11): p. 1156-63.

- 815 19. Howes, S.C., et al., *Effects of tubulin acetylation and tubulin acetyltransferase binding on*
816 *microtubule structure*. Mol Biol Cell, 2014. **25**(2): p. 257-66.
- 817 20. Coombes, C., et al., *Mechanism of microtubule lumen entry for the alpha-tubulin*
818 *acetyltransferase enzyme alphaTAT1*. Proc Natl Acad Sci U S A, 2016. **113**(46): p. E7176-
819 E7184.
- 820 21. Even, A., et al., *ATAT1-enriched vesicles promote microtubule acetylation via axonal*
821 *transport*. Sci Adv, 2019. **5**(12): p. eaax2705.
- 822 22. Ly, N., et al., *alphaTAT1 controls longitudinal spreading of acetylation marks from open*
823 *microtubules extremities*. Sci Rep, 2016. **6**: p. 35624.
- 824 23. Montagnac, G., et al., *alphaTAT1 catalyses microtubule acetylation at clathrin-coated pits*.
825 Nature, 2013. **502**(7472): p. 567-70.
- 826 24. Kalebic, N., et al., *alphaTAT1 is the major alpha-tubulin acetyltransferase in mice*. Nat
827 Commun, 2013. **4**: p. 1962.
- 828 25. Morley, S.J., et al., *Acetylated tubulin is essential for touch sensation in mice*. Elife, 2016.
829 **5**.
- 830 26. Yan, C., et al., *Microtubule Acetylation Is Required for Mechanosensation in Drosophila*.
831 Cell Rep, 2018. **25**(4): p. 1051-1065 e6.
- 832 27. Van Helleputte, L., et al., *Inhibition of histone deacetylase 6 (HDAC6) protects against*
833 *vincristine-induced peripheral neuropathies and inhibits tumor growth*. Neurobiol Dis,
834 2018. **111**: p. 59-69.
- 835 28. d'Ydewalle, C., et al., *HDAC6 inhibitors reverse axonal loss in a mouse model of mutant*
836 *HSPB1-induced Charcot-Marie-Tooth disease*. Nat Med, 2011. **17**(8): p. 968-74.
- 837 29. Picci, C., et al., *HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates*
838 *CMT2A peripheral neuropathy in mice*. Exp Neurol, 2020. **328**: p. 113281.
- 839 30. Morena, J., A. Gupta, and J.C. Hoyle, *Charcot-Marie-Tooth: From Molecules to Therapy*.
840 Int J Mol Sci, 2019. **20**(14).
- 841 31. Feely, S.M., et al., *MFN2 mutations cause severe phenotypes in most patients with CMT2A*.
842 Neurology, 2011. **76**(20): p. 1690-6.
- 843 32. Dorn, G.W., 2nd, *Mitofusin 2 Dysfunction and Disease in Mice and Men*. Front Physiol,
844 2020. **11**: p. 782.
- 845 33. Filadi, R., D. Pendin, and P. Pizzo, *Mitofusin 2: from functions to disease*. Cell Death Dis,
846 2018. **9**(3): p. 330.
- 847 34. Larrea, D., et al., *MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-*
848 *associated ER membrane function but do not impair bioenergetics*. Hum Mol Genet, 2019.
849 **28**(11): p. 1782-1800.
- 850 35. Baloh, R.H., et al., *Altered axonal mitochondrial transport in the pathogenesis of Charcot-*
851 *Marie-Tooth disease from mitofusin 2 mutations*. J Neurosci, 2007. **27**(2): p. 422-30.
- 852 36. Schiavon, C.R., G.S. Shadel, and U. Manor, *Impaired Mitochondrial Mobility in Charcot-*
853 *Marie-Tooth Disease*. Front Cell Dev Biol, 2021. **9**: p. 624823.
- 854 37. Palau, F., et al., *The role of mitochondrial network dynamics in the pathogenesis of*
855 *Charcot-Marie-Tooth disease*. Adv Exp Med Biol, 2009. **652**: p. 129-37.
- 856 38. Cosson, P., et al., *Mitofusin-2 independent juxtaposition of endoplasmic reticulum and*
857 *mitochondria: an ultrastructural study*. PLoS One, 2012. **7**(9): p. e46293.
- 858 39. Filadi, R., et al., *Mitofusin 2 ablation increases endoplasmic reticulum-mitochondria*
859 *coupling*. Proc Natl Acad Sci U S A, 2015. **112**(17): p. E2174-81.

- 860 40. Filadi, R., P. Theurey, and P. Pizzo, *The endoplasmic reticulum-mitochondria coupling in*
861 *health and disease: Molecules, functions and significance*. Cell Calcium, 2017. **62**: p. 1-
862 15.
- 863 41. Han, S., et al., *The role of Mfn2 in the structure and function of endoplasmic reticulum-*
864 *mitochondrial tethering in vivo*. J Cell Sci, 2021. **134**(13).
- 865 42. Bassot, A., et al., *Loss and gain of function of Grp75 or mitofusin 2 distinctly alter*
866 *cholesterol metabolism, but all promote triglyceride accumulation in hepatocytes*. Biochim
867 Biophys Acta Mol Cell Biol Lipids, 2021. **1866**(12): p. 159030.
- 868 43. Misko, A., et al., *Mitofusin 2 Is Necessary for Transport of Axonal Mitochondria and*
869 *Interacts with the Miro/Milton Complex*. Journal of Neuroscience, 2010. **30**(12): p. 4232-
870 4240.
- 871 44. Misko, A.L., et al., *Mitofusin2 mutations disrupt axonal mitochondrial positioning and*
872 *promote axon degeneration*. J Neurosci, 2012. **32**(12): p. 4145-55.
- 873 45. Mou, Y., et al., *MFN2 Deficiency Impairs Mitochondrial Transport and Downregulates*
874 *Motor Protein Expression in Human Spinal Motor Neurons*. Front Mol Neurosci, 2021.
875 **14**: p. 727552.
- 876 46. Zhou, Y., et al., *Restoring mitofusin balance prevents axonal degeneration in a Charcot-*
877 *Marie-Tooth type 2A model*. J Clin Invest, 2019. **129**(4): p. 1756-1771.
- 878 47. de Brito, O.M. and L. Scorrano, *Mitofusin 2 tethers endoplasmic reticulum to*
879 *mitochondria*. Nature, 2008. **456**(7222): p. 605-10.
- 880 48. Aumeier, C., et al., *Self-repair promotes microtubule rescue*. Nat Cell Biol, 2016. **18**(10):
881 p. 1054-1064.
- 882 49. Atherton, J., et al., *Microtubule architecture in vitro and in cells revealed by cryo-electron*
883 *tomography*. Acta Crystallogr D Struct Biol, 2018. **74**(Pt 6): p. 572-584.
- 884 50. Triclin, S., et al., *Self-repair protects microtubules from destruction by molecular motors*.
885 Nat Mater, 2021. **20**(6): p. 883-891.
- 886 51. Andreu-Carbo, M., et al., *Motor usage imprints microtubule stability along the shaft*. Dev
887 Cell, 2022. **57**(1): p. 5-18 e8.
- 888 52. Zilberman, Y., et al., *Regulation of microtubule dynamics by inhibition of the tubulin*
889 *deacetylase HDAC6*. J Cell Sci, 2009. **122**(Pt 19): p. 3531-41.
- 890 53. Bartolini, F., et al., *An mDial-1/INF2 formin activation cascade facilitated by IQGAP1*
891 *regulates stable microtubules in migrating cells*. Mol Biol Cell, 2016. **27**(11): p. 1797-808.
- 892 54. Area-Gomez, E., et al., *Upregulated function of mitochondria-associated ER membranes*
893 *in Alzheimer disease*. EMBO J, 2012. **31**(21): p. 4106-23.
- 894 55. Area-Gomez, E. and E.A. Schon, *On the Pathogenesis of Alzheimer's Disease: The MAM*
895 *Hypothesis*. FASEB J, 2017. **31**(3): p. 864-867.
- 896 56. Montesinos, J., et al., *The Alzheimer's disease-associated C99 fragment of APP regulates*
897 *cellular cholesterol trafficking*. EMBO J, 2020. **39**(20): p. e103791.
- 898 57. Bienias, K., et al., *Regulation of sphingomyelin metabolism*. Pharmacol Rep, 2016. **68**(3):
899 p. 570-81.
- 900 58. Grimm, M.O., et al., *Regulation of cholesterol and sphingomyelin metabolism by amyloid-*
901 *beta and presenilin*. Nat Cell Biol, 2005. **7**(11): p. 1118-23.
- 902 59. Barbullushi, K., et al., *Disease Modeling and Therapeutic Strategies in CMT2A: State of*
903 *the Art*. Mol Neurobiol, 2019. **56**(9): p. 6460-6471.
- 904 60. El Fissi, N., et al., *Mitofusin gain and loss of function drive pathogenesis in Drosophila*
905 *models of CMT2A neuropathy*. EMBO Rep, 2018. **19**(8).

- 906 61. Zuchner, S., et al., *Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-*
907 *Marie-Tooth neuropathy type 2A*. Nat Genet, 2004. **36**(5): p. 449-51.
- 908 62. Chung, K.W., et al., *Early onset severe and late-onset mild Charcot-Marie-Tooth disease*
909 *with mitofusin 2 (MFN2) mutations*. Brain, 2006. **129**(Pt 8): p. 2103-18.
- 910 63. Zuchner, S., et al., *Axonal neuropathy with optic atrophy is caused by mutations in*
911 *mitofusin 2*. Ann Neurol, 2006. **59**(2): p. 276-81.
- 912 64. Detmer, S.A. and D.C. Chan, *Complementation between mouse Mfn1 and Mfn2 protects*
913 *mitochondrial fusion defects caused by CMT2A disease mutations*. Journal of Cell Biology,
914 2007. **176**(4): p. 405-414.
- 915 65. Devine, M.J., N. Birsa, and J.T. Kittler, *Miro sculpts mitochondrial dynamics in neuronal*
916 *health and disease*. Neurobiol Dis, 2016. **90**: p. 27-34.
- 917 66. Davis, K., et al., *Miro GTPase domains regulate the assembly of the mitochondrial motor-*
918 *adaptor complex*. Life Sci Alliance, 2023. **6**(1).
- 919 67. Park, H.J., et al., *A novel INF2 mutation in a Korean family with autosomal dominant*
920 *intermediate Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis*. J
921 Peripher Nerv Syst, 2014. **19**(2): p. 175-9.
- 922 68. Davenport, A.M., et al., *Structural and functional characterization of the alpha-tubulin*
923 *acetyltransferase MEC-17*. J Mol Biol, 2014. **426**(14): p. 2605-16.
- 924 69. Pero, M.E., et al., *Pathogenic role of delta 2 tubulin in bortezomib-induced peripheral*
925 *neuropathy*. Proceedings of the National Academy of Sciences of the United States of
926 America, 2021. **118**(4).
- 927 70. Qu, X., et al., *Activity-Dependent Nucleation of Dynamic Microtubules at Presynaptic*
928 *Boutons Controls Neurotransmission*. Curr Biol, 2019. **29**(24): p. 4231-4240 e5.
- 929 71. Khawaja, S., G.G. Gundersen, and J.C. Bulinski, *Enhanced stability of microtubules*
930 *enriched in deetyrosinated tubulin is not a direct function of deetyrosination level*. J Cell
931 Biol, 1988. **106**(1): p. 141-9.
- 932 72. Bligh, E.G. and W.J. Dyer, *A rapid method of total lipid extraction and purification*. Can
933 J Biochem Physiol, 1959. **37**(8): p. 911-7.
- 934 73. Vance, J.E., *Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two*
935 *metabolically related aminophospholipids*. J Lipid Res, 2008. **49**(7): p. 1377-87.
- 936 74. Shin, G.J., et al., *Integrins protect sensory neurons in models of paclitaxel-induced*
937 *peripheral sensory neuropathy*. Proc Natl Acad Sci U S A, 2021. **118**(15).

938